Literature DB >> 776466

Immunological enhancement in the pathogenesis of pyelonephritis.

T E Miller, S Burnham, J D North.   

Abstract

The role of the immune response in pyelonephritis was investigated by manipulation of the host's immune capacity using the immunosuppressive drugs 6-mercaptopurine, cyclophosphamide and thiamphenicol. Treatment with 6-mercaptopurine depressed the humoral immune response but did not have an adverse effect on the course of renal infection. Thiamphenicol administration prevented the development of pathological lesions but this was due to the anti-bacterial activity of thiamphenicol and not to its immunosuppressive activity. Pyelonephritic animals treated with cyclophosphamide did not produce anti-bacterial antibody. Despite this, cyclophosphamide-treated animals were able to eliminate organisms more readily from the infected kidney than untreated animals with a normal humoral immune response. We believe that blocking of the phenomenon of immunological enhancement explains these unexpected results and that the immune response to renal infection may have an immunoenhancing role protecting the bacterial cell from otherwise effective host defence mechanisms.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 776466      PMCID: PMC1538419     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  14 in total

1.  Isolation and characterization of a serum antibactericidal factor.

Authors:  P W Taylor
Journal:  Clin Sci       Date:  1972-11       Impact factor: 6.124

2.  Experimental pyelonephritis: a new method for inducing pyelonephritis in the rat.

Authors:  T E Miller; K B Robinson
Journal:  J Infect Dis       Date:  1973-03       Impact factor: 5.226

3.  Significance of amount and avidity of E. coli O antibodies for manifestation of their serological and protective properties. A preliminary study.

Authors:  S Ahlstedt; J Holmgren; L A Hanson
Journal:  Int Arch Allergy Appl Immunol       Date:  1972

4.  Comparative studies of immunoglobulin opsonins in osteomyelitis and other established infections.

Authors:  R C Williams; J H Dossett; P G Quie
Journal:  Immunology       Date:  1969-08       Impact factor: 7.397

5.  Functional aspects of the selective depletion of lymphoid tissue by cyclophosphamide.

Authors:  J L Turk; D Parker; L W Poulter
Journal:  Immunology       Date:  1972-10       Impact factor: 7.397

Review 6.  Immunological facilitation, a broadening of the concept of the enhancement phenomenon.

Authors:  G A Voisin
Journal:  Prog Allergy       Date:  1971

7.  Local immune response in experimental pyelonephritis.

Authors:  J D Lehmann; J W Smith; T E Miller; J A Barnett; J P Sanford
Journal:  J Clin Invest       Date:  1969-11       Impact factor: 14.808

8.  Bacterial blocking activity of specific IgG in chronic Pseudomonas aeruginosa infection.

Authors:  R M Guttman; B A Waisbren
Journal:  Clin Exp Immunol       Date:  1975-01       Impact factor: 4.330

9.  Potentiation of T-cell-mediated immunity by selective suppression of antibody formation with cyclophosphamide.

Authors:  P H Lagrange; G B Mackaness; T E Miller
Journal:  J Exp Med       Date:  1974-06-01       Impact factor: 14.307

10.  Retrograde Proteus pyelonephritis in rats. Localization of antigen and antibody in treated sterile pyelonephritic kidneys.

Authors:  R S COTRAN
Journal:  J Exp Med       Date:  1963-05-01       Impact factor: 14.307

View more
  3 in total

1.  Modification by suppressor cells and serum factors of the cell-mediated immune response in experimental pyelonephritis.

Authors:  T Miller; L Scott; E Stewart; D North
Journal:  J Clin Invest       Date:  1978-04       Impact factor: 14.808

2.  B lymphocyte colony formation in renal infection.

Authors:  T Miller; S Rawstorn; E Stewart
Journal:  Infect Immun       Date:  1979-06       Impact factor: 3.441

Review 3.  The inflammatory response and tissue damage. The example of renal scars following acute renal infection.

Authors:  M P Glauser; P Meylan; J Bille
Journal:  Pediatr Nephrol       Date:  1987-10       Impact factor: 3.714

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.